Stockpolly
Search
IMA · NASDAQ · Biotechnology

ImageneBio (IMA)

Develops IMG-007 for autoimmune and inflammatory diseases.

$5.01
At close−0.01 (−0.20%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue110000100000
Cost of revenue0010075000100
Gross profit10−100−7−5100−100
202291568792781212
Research & development1141010754416567
6865583411065
General & administrative6865583411065
Other expenses130−70−6−4000300
Operating income−20−22−18−16−12−13−6−9−27−9−12−12
222223062112
Interest income222222111211
Interest expense010000000000
Other non-operating income0−4−3−1−1000−2−10−2
Income before tax−17−20−16−14−10−9−6−3−25−7−11−10
Income tax expense000000000000
Net income from continuing operations−17−19−16−14−10−9−6−3−25−7−11−10
Net income−17−19−16−14−10−9−6−3−25−7−11−10
EPS, basic−$0.40−$4.89−$4.01−$3.41−$4.41−$5.58−$6.47−$4.46−$3.01−$0.62−$0.95−$0.63
EPS, diluted−$0.40−$4.89−$4.01−$3.41−$4.41−$5.58−$6.47−$4.46−$3.01−$0.62−$0.95−$0.63
Weighted average shares, basic4344411129111116
Weighted average shares, diluted4344411129111116
EBITDA−19−18−15−15−12−12−6−8−24−7−12−10
Depreciation & amortization000000000100
EBIT−20−18−16−15−12−12−6−8−25−7−12−10